Ionis Cuts Tryngolza Price 93% to Spur FDA‑Approved Expansion in FCS and sHTG
Ionis slashes Tryngolza price by 93% ahead of FDA approval, aiming to boost FCS and sHTG uptake and lift stock upside to $106.
3 minutes to read
Ionis Pharmaceuticals Inc
Ionis Boosts 2026 Outlook: Tryngolza Sales Hit $2 Billion Goal
Ionis Pharmaceuticals doubles Tryngolza sales forecast to $2 billion, positioning itself for robust 2026 growth amid a strong antisense oligonucleotide launch and strategic partnerships.
3 minutes to read
Ionis Pharmaceuticals Soars with Breakthroughs in RNA-Targeted Therapies and Positive Trial Results
Ionis Pharmaceuticals Inc has made significant breakthroughs in biotechnology, including a 31% surge in stock value and positive Phase-III data for its drug Olezarsen, highlighting the company’s potential to revolutionize the treatment of severe blo…
3 minutes to read
Ionis Pharmaceuticals Soars with Promising Therapy Developments and Analyst Endorsements
Ionis Pharmaceuticals Inc. continues to demonstrate steady growth and promise, driven by positive developments in its RNA-targeted drug discovery and development, as well as analyst confidence and strategic endorsements.
2 minutes to read
Ionis Pharmaceuticals Faces Financial Ups and Downs Amid Analyst Confidence and Trading Suspension
Ionis Pharmaceuticals Inc. faces a mixed bag of financial news, with declining stock value and trading suspension, but also reaffirmed analyst confidence and a growing HDAC inhibitors market.
3 minutes to read
Ionis Pharmaceuticals: Leading RNA-Targeted Innovations Amid Market Challenges
Ionis Pharmaceuticals Inc remains a leader in biotechnology, driven by innovative research and strategic partnerships, despite facing financial challenges.
3 minutes to read